(BRKR) Bruker - Ratings and Ratios
Spectrometers, Microscopes, Imaging, Diagnostic, Superconductors
BRKR EPS (Earnings per Share)
BRKR Revenue
Description: BRKR Bruker
Bruker Corporation is a leading global provider of scientific instruments and analytical solutions, operating across four business segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers a diverse range of products and services, including magnetic resonance spectroscopy, preclinical imaging, and life science mass spectrometry, catering to various industries such as pharmaceuticals, biotechnology, and academia.
From a financial perspective, Bruker Corporation has a market capitalization of $6.635 billion, indicating a significant presence in the Life Sciences Tools & Services sub-industry. To further evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin can be analyzed. For instance, a high gross margin could indicate a strong pricing power and competitive advantage, while a rising operating margin may suggest effective cost management and operational efficiency.
Bruker Corporations product portfolio is diverse, with a range of offerings that cater to different customer needs. The companys focus on innovation is evident from its investments in research and development, which enables it to stay ahead in the competitive landscape. To assess the companys growth prospects, metrics such as R&D expenditure as a percentage of revenue, new product pipeline, and customer adoption rates can be examined.
From a valuation perspective, Bruker Corporations price-to-earnings (P/E) ratio of 84.21 and forward P/E of 17.95 suggest that the stock may be overvalued relative to its current earnings. However, the companys return on equity (RoE) of 4.41% indicates that it may not be generating sufficient returns on shareholder capital. To gain a deeper understanding of the companys valuation, metrics such as enterprise value-to-EBITDA (EV/EBITDA) and price-to-book (P/B) ratio can be analyzed.
BRKR Stock Overview
| Market Cap in USD | 4,690m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2000-08-04 |
BRKR Stock Ratings
| Growth Rating | -67.1% |
| Fundamental | 44.2% |
| Dividend Rating | 47.9% |
| Return 12m vs S&P 500 | -58.5% |
| Analyst Rating | 3.86 of 5 |
BRKR Dividends
| Dividend Yield 12m | 0.52% |
| Yield on Cost 5y | 0.52% |
| Annual Growth 5y | 4.56% |
| Payout Consistency | 96.5% |
| Payout Ratio | 13.2% |
BRKR Growth Ratios
| Growth Correlation 3m | -76% |
| Growth Correlation 12m | -91.5% |
| Growth Correlation 5y | -24.7% |
| CAGR 5y | -15.18% |
| CAGR/Max DD 3y | -0.22 |
| CAGR/Mean DD 3y | -0.61 |
| Sharpe Ratio 12m | -1.55 |
| Alpha | -68.35 |
| Beta | 0.875 |
| Volatility | 63.32% |
| Current Volume | 5977.2k |
| Average Volume 20d | 2826.7k |
| Stop Loss | 30.4 (-5.2%) |
| Signal | -1.42 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (79.6m TTM) > 0 and > 6% of Revenue (6% = 206.6m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -2.07pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 23.68% (prev 27.20%; Δ -3.52pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 165.9m > Net Income 79.6m (YES >=105%, WARN >=100%) |
| Net Debt (2.34b) to EBITDA (400.3m) ratio: 5.85 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.61 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (151.8m) change vs 12m ago 2.57% (target <= -2.0% for YES) |
| Gross Margin 48.00% (prev 49.91%; Δ -1.91pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 56.24% (prev 52.85%; Δ 3.39pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.39 (EBITDA TTM 400.3m / Interest Expense TTM 56.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.84
| (A) 0.13 = (Total Current Assets 2.16b - Total Current Liabilities 1.35b) / Total Assets 6.34b |
| (B) 0.38 = Retained Earnings (Balance) 2.42b / Total Assets 6.34b |
| (C) 0.03 = EBIT TTM 189.9m / Avg Total Assets 6.12b |
| (D) 0.52 = Book Value of Equity 2.32b / Total Liabilities 4.47b |
| Total Rating: 2.84 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 44.19
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield 0.70% = 0.35 |
| 3. FCF Margin 1.43% = 0.36 |
| 4. Debt/Equity 1.34 = 1.67 |
| 5. Debt/Ebitda 6.08 = -2.50 |
| 6. ROIC - WACC -3.58% = -4.47 |
| 7. RoE 4.40% = 0.37 |
| 8. Rev. Trend 75.73% = 3.79 |
| 9. Rev. CAGR 8.39% = 1.05 |
| 10. EPS Trend -76.34% = -1.91 |
| 11. EPS CAGR -59.29% = -2.50 |
What is the price of BRKR shares?
Over the past week, the price has changed by +4.12%, over one month by -4.33%, over three months by -17.94% and over the past year by -50.71%.
Is Bruker a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BRKR is around 25.88 USD . This means that BRKR is currently overvalued and has a potential downside of -19.3%.
Is BRKR a buy, sell or hold?
- Strong Buy: 5
- Buy: 2
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BRKR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 46.7 | 45.7% |
| Analysts Target Price | 46.7 | 45.7% |
| ValueRay Target Price | 28.4 | -11.6% |
Last update: 2025-09-16 04:32
BRKR Fundamental Data Overview
CCE Cash And Equivalents = 92.0m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 59.4423
P/E Forward = 12.2699
P/S = 1.3622
P/B = 2.5996
P/EG = 3.64
Beta = 1.213
Revenue TTM = 3.44b USD
EBIT TTM = 189.9m USD
EBITDA TTM = 400.3m USD
Long Term Debt = 2.38b USD (from longTermDebt, last quarter)
Short Term Debt = 55.7m USD (from shortTermDebt, last quarter)
Debt = 2.44b USD (Calculated: Short Term 55.7m + Long Term 2.38b)
Net Debt = 2.34b USD (from netDebt column, last quarter)
Enterprise Value = 7.03b USD (4.69b + Debt 2.44b - CCE 92.0m)
Interest Coverage Ratio = 3.39 (Ebit TTM 189.9m / Interest Expense TTM 56.0m)
FCF Yield = 0.70% (FCF TTM 49.3m / Enterprise Value 7.03b)
FCF Margin = 1.43% (FCF TTM 49.3m / Revenue TTM 3.44b)
Net Margin = 2.31% (Net Income TTM 79.6m / Revenue TTM 3.44b)
Gross Margin = 48.00% ((Revenue TTM 3.44b - Cost of Revenue TTM 1.79b) / Revenue TTM)
Tobins Q-Ratio = 3.03 (Enterprise Value 7.03b / Book Value Of Equity 2.32b)
Interest Expense / Debt = 0.64% (Interest Expense 15.7m / Debt 2.44b)
Taxrate = 44.18% (91.4m / 206.9m)
NOPAT = 106.0m (EBIT 189.9m * (1 - 44.18%))
Current Ratio = 1.61 (Total Current Assets 2.16b / Total Current Liabilities 1.35b)
Debt / Equity = 1.34 (Debt 2.44b / last Quarter total Stockholder Equity 1.82b)
Debt / EBITDA = 6.08 (Net Debt 2.34b / EBITDA 400.3m)
Debt / FCF = 49.40 (Debt 2.44b / FCF TTM 49.3m)
Total Stockholder Equity = 1.81b (last 4 quarters mean)
RoA = 1.26% (Net Income 79.6m, Total Assets 6.34b )
RoE = 4.40% (Net Income TTM 79.6m / Total Stockholder Equity 1.81b)
RoCE = 4.53% (Ebit 189.9m / (Equity 1.81b + L.T.Debt 2.38b))
RoIC = 2.63% (NOPAT 106.0m / Invested Capital 4.04b)
WACC = 6.20% (E(4.69b)/V(7.12b) * Re(9.24%)) + (D(2.44b)/V(7.12b) * Rd(0.64%) * (1-Tc(0.44)))
Shares Correlation 3-Years: 27.27 | Cagr: 0.19%
Discount Rate = 9.24% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 71.50% ; FCFE base≈96.8m ; Y1≈84.2m ; Y5≈67.5m
Fair Price DCF = 6.60 (DCF Value 1.00b / Shares Outstanding 151.7m; 5y FCF grow -15.96% → 3.0% )
Revenue Correlation: 75.73 | Revenue CAGR: 8.39%
Rev Growth-of-Growth: -5.94
EPS Correlation: -76.34 | EPS CAGR: -59.29%
EPS Growth-of-Growth: -58.26
Additional Sources for BRKR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle